ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GLFD Guilford Pharmaceuticals (MM)

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Guilford Pharmaceuticals (MM) NASDAQ:GLFD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

Guilford Pharmaceuticals to Announce Third Quarter 2004 Financial Results on Monday, November 8, 2004

05/11/2004 1:30pm

PR Newswire (US)


Guilford (NASDAQ:GLFD)
Historical Stock Chart


From Dec 2019 to Dec 2024

Click Here for more Guilford Charts.
Guilford Pharmaceuticals to Announce Third Quarter 2004 Financial Results on Monday, November 8, 2004 BALTIMORE, Nov. 5 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (NASDAQ:GLFD) will announce its third quarter 2004 financial results on Monday, November 8, 2004 and will also host a conference call and live audio webcast beginning at 4:00 p.m. E.T. The press release and live webcast can be accessed by going to the Investor Relations section of Guilford's website at http://www.guilfordpharm.com/. Following the webcast, an archived version of the call will be available until Monday, November 22, 2004. To participate in the live conference call, U.S. residents should dial 800-299-7928, international callers 617-614-3926. The participant passcode is 68168189. An audio replay of the conference call will be available for 72 hours beginning at approximately 6:00 p.m. E.T. on November 8, 2004 through 6:00 p.m. November 11, 2004. To access the replay, U.S. residents should dial 888-286-8010, (int'l callers 617-801-6888), passcode 45654677. Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT(R) Injection (tirofiban hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection. For additional information about GLIADEL(R) Wafer, please visit http://www.gliadel.com/; and for AGGRASTAT(R) Injection, please see http://www.aggrastat.com/. CONTACT: Stacey Jurchison, Guilford Pharmaceuticals Inc., +1-410-631-5022, DATASOURCE: Guilford Pharmaceuticals Inc. CONTACT: Stacey Jurchison, Guilford Pharmaceuticals Inc., +1-410-631-5022, Web site: http://www.gliadel.com/ Web site: http://www.aggrastat.com/ Web site: http://www.guilfordpharm.com/ Company News On-Call: http://www.prnewswire.com/comp/112882.html

Copyright

1 Year Guilford Chart

1 Year Guilford Chart

1 Month Guilford Chart

1 Month Guilford Chart

Your Recent History

Delayed Upgrade Clock